UBS raised the firm’s price target on United Therapeutics (UTHR) to $560 from $415 and keeps a Buy rating on the shares. The stock is up 28% on the “successful” Phase 3 TETON-2 readout, which came as a positive surprise, the analyst tells investors in a research note. The firm sees further upside as Tyvaso’s Idiopathic Pulmonary Fibrosis opportunity is yet to be fully priced in, UBS says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Buy Rating for United Therapeutics: Promising TETON-2 Trial Results Highlight Tyvaso’s Potential in IPF Treatment
- United Therapeutics’ Tyvaso Shines in Phase III Trial, Poised for Growth in IPF Market
- Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market Uncertainties
- United Therapeutics: Hold Rating Amid Positive TETON-2 Results and Competitive Challenges
- United Therapeutics Stock (UTHR) Rockets 40% on Clinical Trial Results